Type 2 Diabetes Mellitus Clinical Trial
— Delish R33Official title:
Optimizing Lifestyle Interventions With Mindfulness-based Strategies in Type 2 Diabetes
Verified date | June 2021 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators plan an R33 phase trial in which 120 persons with type 2 diabetes (T2DM) will be randomized (using a 1:1 ratio) to education alone (Ed) on following a carbohydrate restricted diet for T2DM, or this same education content with added mindful eating/Mindfulness-Based Intervention components (Ed+MBI).
Status | Completed |
Enrollment | 125 |
Est. completion date | June 17, 2021 |
Est. primary completion date | June 17, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. History of T2DM mellitus. 2. HbA1c = 6.5% and < 12.0% at screening. 3. Experience food-related cravings most days of the week and eat in response to these cravings regularly. 4. Aged 18 years old and older. 5. Able to engage in light physical activity. 6. Willing and able to participate in the interventions including appropriate participation in the group setting. 7. Have smartphone and are willing to use it on a regular basis for data collection. 8. Ability to speak English. Exclusion Criteria: 1. Unable to provide informed consent. 2. A substance abuse, mental health, or medical condition that, in the opinion of investigators, will make it difficult for the potential participant to participate in the intervention, that may need immediate changes in medical management that will affect study outcome measures, or that may require important adaptations in the study diet. 3. Pregnant or planning to get pregnant in the next 12 months, breastfeeding or less than 6 months post-partum. 4. Current use of weight loss medications, such as Alli or amphetamine-based drugs that may affect weight. 5. Planned or history of weight-loss (bariatric) surgery, or other intestinal surgeries that cause malabsorption. These are likely to change study outcome measures, making it difficult to distinguish the effects of the intervention program, or require extensive tailoring of the diet intervention. 6. Currently enrolled in a weight loss program, such as Weight Watchers or a self-help group such as Overeaters Anonymous, or have unalterable plans to enroll in one of these programs in the next year; using a ketogenic low carbohydrate diet in the past 6 months with advice from a health care professional; or use of a mindful eating program with guidance from a professional in the past 6 months or have ever used the study mindful-eating app. 7. Vegan or vegetarian. 8. Unwilling to do regular blood testing at home for glucose or ketone monitoring. |
Country | Name | City | State |
---|---|---|---|
United States | Osher Center for Integrative Medicine | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Center for Complementary and Integrative Health (NCCIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | stress-related eating | change in stress-related eating as measured by two questions about stress-related eating from the MIDUS study and one additional stress-related eating question | change from baseline to 12 months | |
Other | Perceived Stress | change in Perceived Stress Scale total score | change from baseline to 12 months | |
Other | Insulin resistance | Homeostatic model assessment (HOMA) index of insulin resistance (computed from insulin and fasting glucose measures) | change from baseline to 12 months | |
Other | Glycemic control--fasting glucose | fasting blood glucose | change from baseline to 12 months | |
Other | Mindfulness | Five-factor mindfulness scale | change from baseline to 12 months | |
Primary | diet adherence between intervention arms as measured by ketones | proportion of ketone measures dichotomized as > or = 0.3 mmol/L versus < 0.3 | measures from ketone measure initiation (week 5) to 12 months | |
Primary | diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous | proportion of participants consuming < 50 grams/day of non-fiber carbohydrate (from 24-hour diet recall) | from 3 to 12 months | |
Secondary | executive functioning /decreased impulsivity-Delayed Discounting | change in Delayed Discounting task score | change from baseline to 12 months | |
Secondary | emotion-related eating | change in emotion-related eating as measured by the Coping subscale of the Palatable Eating Motives Scale (PEMS). | change from baseline to 12 months | |
Secondary | Glycemic control--a1c | hemoglobin a1c | change from baseline to 12 months | |
Secondary | frequency of eating in response to cravings | frequency of eating in response to cravings using ecological momentary assessment (EMA) | change from baseline to 12 months | |
Secondary | diet adherence between intervention arms as measured by 24- hour diet recall--total carbs, continuous | mean grams of non-fiber carbohydrate consumed per day (from 24-hour diet recall) | from 3 to 12 months | |
Secondary | executive functioning /decreased impulsivity--Relative Reinforcing Value of Food (RRVF) | change in RRVF score | change from baseline to 12 months | |
Secondary | Salzburg Stress Eating Scale | change in stress-related eating as measured by Salzburg Stress Eating Scale | change from baseline to 12 months | |
Secondary | dietary resilience (resumption of dietary adherence) after dietary non-adherence occurs | time from a ketone measure of < 0.3 mmol/L to higher levels of >/= 0.3 mmol/L | 12 months | |
Secondary | Weight change | pounds | change from baseline to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|